Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial

苯拉唑马布 医学 安慰剂 鼻息肉 内科学 人口 随机对照试验 哮喘 嗜酸性粒细胞 外科 胃肠病学 美波利祖马布 病理 环境卫生 替代医学
作者
Claus Bachert,Joseph K. Han,Martin Y. Desrosiers,Philippe Gevaert,Enrico Marco Heffler,Claire L Hopkins,Jody R. Tversky,Peter N. Barker,David Cohen,Claire L. Emson,Ubaldo J. Martin,Vivian H. Shih,Sofia Necander,James L. Kreindler,Maria L. Jison,Viktoría Werkström
出处
期刊:The Journal of Allergy and Clinical Immunology [Elsevier BV]
卷期号:149 (4): 1309-1317.e12 被引量:380
标识
DOI:10.1016/j.jaci.2021.08.030
摘要

Eosinophilic inflammation has been implicated in the pathogenesis, severity, and treatment responsiveness of chronic rhinosinusitis with nasal polyps (CRSwNP).We sought to assess the efficacy and safety of benralizumab-mediated eosinophil depletion for treating CRSwNP.The phase 3 OSTRO study enrolled patients with severe CRSwNP who were symptomatic despite treatment with intranasal corticosteroids and who had a history of systemic corticosteroid (SCS) use and/or surgery for nasal polyps (NP). Patients were randomized 1:1 to treatment with benralizumab 30 mg or placebo every 4 weeks for the first 3 doses and every 8 weeks thereafter. Coprimary end points were change from baseline to week 40 in NP score (NPS) and patient-reported mean nasal blockage score reported once every 2 weeks.The study population comprised 413 randomized patients (207 in the benralizumab group and 206 in the placebo group). Benralizumab significantly improved NPS and nasal blockage score compared to placebo at week 40 (P ≤ .005). Improvements in Sinonasal Outcome Test 22 score at week 40, time to first NP surgery and/or SCS use for NP, and time to first NP surgery were not statistically significant between treatment groups. Nominal significance was obtained for improvement in difficulty in sense of smell score at week 40 (P = .003). Subgroup analyses suggested influences of comorbid asthma, number of NP surgeries, sex, body mass index, and baseline blood eosinophil count on treatment effects. Benralizumab was safe and well tolerated.Benralizumab, when added to standard-of-care therapy, reduced NPS, decreased nasal blockage, and reduced difficulty with sense of smell compared to placebo in patients with CRSwNP.ClinicalTrials.gov NCT03401229.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ryan完成签到,获得积分10
1秒前
1秒前
丘比特的应助被4yjmngbfd采纳,获得10
1秒前
1秒前
xiaot驳回了Jun的应助
2秒前
2秒前
张娜发布了新的文献求助10
2秒前
禾十完成签到,获得积分10
3秒前
康利萍完成签到,获得积分20
3秒前
4秒前
牧长一完成签到 ,获得积分0
4秒前
5秒前
w0304hf完成签到,获得积分10
5秒前
路星辞完成签到 ,获得积分10
5秒前
ShawnJohn发布了新的文献求助10
5秒前
6秒前
6秒前
禾十发布了新的文献求助10
6秒前
大个的应助被Ann采纳,获得10
7秒前
8秒前
8秒前
康利萍发布了新的文献求助10
8秒前
8秒前
DW的应助被小博士328采纳,获得10
9秒前
pengnanhao完成签到,获得积分10
9秒前
10秒前
10秒前
10秒前
10秒前
My_magnum_opus的应助被周周采纳,获得30
10秒前
顾矜的应助被vbmc采纳,获得30
11秒前
仁爱嫣完成签到,获得积分10
11秒前
cheesejiang完成签到,获得积分10
11秒前
12秒前
安静海露发布了新的文献求助10
12秒前
安静海露发布了新的文献求助10
12秒前
小民完成签到 ,获得积分10
13秒前
6366336发布了新的文献求助10
13秒前
云郁闷完成签到,获得积分10
15秒前
WangY发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183621
求助须知:如何正确求助?哪些是违规求助? 9572918
关于积分的说明 21828010
捐赠科研通 7780809
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558243
邀请新用户注册赠送积分活动 2480496